Statins alone are not always adequate therapy to achieve low-density lipoprotein (LDL) goals in many patients. Many options are available either alone or in combination with statins that makes it possible to reach recommended goals in a safe and tolerable fashion for most patients. Ezetimibe and bile acid sequestrants reduce cholesterol transport to the liver and can be used in combination. Niacin is very effective at lowering LDL, beyond its ability to raise high-density lipoprotein and shift LDL particle size to a less atherogenic type. When statins cannot be tolerated at all, red yeast rice can be used if proper formulations of the product are obtained. Nutrients can also be added to the diet, including plant stanols and sterols, soy protein, almonds, and fiber, either individually or all together as a portfolio diet. A clear understanding of how each of these strategies works is essential for effective results.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252497 | PMC |
| http://dx.doi.org/10.1007/s11883-011-0222-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Toward a biological definition of neuronal and glial synucleinopathies.
Nat Med
January 2025
Department of Neurology & Neurological Sciences, Stanford Movement Disorders Center, Stanford University, Stanford, CA, USA.
Cerebral accumulation of alpha-synuclein (αSyn) aggregates is the hallmark event in a group of neurodegenerative diseases-collectively called synucleinopathies-which include Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Currently, these are diagnosed by their clinical symptoms and definitively confirmed postmortem by the presence of αSyn deposits in the brain. Here, we summarize the drawbacks of the current clinical definition of synucleinopathies and outline the rationale for moving toward an earlier, biology-anchored definition of these disorders, with or without the presence of clinical symptoms.
View Article and Find Full Text PDFPhysiologically based pharmacokinetic modeling of small molecules: How much progress have we made?
Drug Metab Dispos
January 2025
Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington. Electronic address:
Physiologically based pharmacokinetic (PBPK) models of small molecules have become mainstream in drug development and in academic research. The use of PBPK models is continuously expanding, with the majority of work now focusing on predictions of drug-drug interactions, drug-disease interactions, and changes in drug disposition across lifespan. Recently, publications that use PBPK modeling to predict drug disposition during pregnancy and in organ impairment have increased reflecting the advances in incorporating diverse physiologic changes into the models.
View Article and Find Full Text PDFSystematic literature review on Calcium Pyrophosphate Deposition (CPPD) nomenclature: condition elements and clinical states- A Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus project.
RMD Open
January 2025
Rheumatology Department, IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy
Objectives: The Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) has developed a calcium pyrophosphate deposition (CPPD) nomenclature project. This systematic literature review constituted its first step and aimed to provide a state-of-the-art analysis of the medical literature of the last 20 years.
Methods: A systematic literature search was undertaken in the , and databases between 2000 and 2022, restricted to studies on humans and in the English language.
IUPHAR review: Drug Repurposing in Schizophrenia - An Updated Review of Clinical Trials.
Pharmacol Res
January 2025
Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK. Electronic address:
There is an urgent need for mechanistically novel and more efficacious treatments for schizophrenia, especially those targeting negative and cognitive symptoms with a more favorable side-effect profile. Drug repurposing-the process of identifying new therapeutic uses for already approved compounds-offers a promising approach to overcoming the lengthy, costly, and high-risk process of traditional CNS drug discovery. This review aims to update our previous findings on the clinical drug repurposing pipeline in schizophrenia.
View Article and Find Full Text PDFAn exploration into the experiences of newly qualified midwives during their transition to practice in the UK: A systematic review.
Midwifery
January 2025
Faculty of Health Sciences, University of Hull, Cottingham Road, Hull, United Kingdom.
Aim: The aim of this systematic review was to explore the experiences of newly qualified midwives (NQMs) during their transition to practice in the UK.
Background: It has been recognised that the transition from student to NQM is a time of significant change that has implications for staff recruitment and retention. Thus, the rationale for this review was that understanding the experiences of NQMs at this crucial time in their career is essential for developing systems of support to improve maternity care and no previous reviews were found on this topic based in the UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!